Given the robust associations of PELI1 overexpression with key biological and clinical features—including DNA methylation patterns, m6A modification dynamics, patient survival, diagnostic potential, and tumor mutation burden—identified in our prior analyses, we selected LIHC as a representative malignancy for in-depth expression profiling. The gene discussed is PELI1; the disease is neoplasm.